VYNE Therapeutics reports a deeper-than-expected Q2 loss, missing estimates by $1.92 per share amid ongoing cash burn.
VYNE Therapeutics posted a Q2 GAAP loss of $2.14 per share, missing expectations by $1.92. The wider-than-anticipated loss reflects ongoing operational costs and investment in pipeline development.
As of June 30, 2026, the company held $18.7 million in cash and cash equivalents. VYNE expects its current cash, combined with $100 million from recent private financings, to sustain operations into 2028.
The company did not disclose immediate market reactions to the earnings miss.